Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,684,945 | $223,855 | $814,474 | $1,024,680 |
| - Cash | $71,335 | $88,398 | $53,641 | $96,449 |
| + Debt | $110,585 | $205,916 | $202,543 | $77,557 |
| Enterprise Value | $1,724,195 | $341,373 | $963,376 | $1,005,788 |
| Revenue | $196,542 | $59,606 | $3,686 | $0 |
| % Growth | 229.7% | 1,517.1% | – | – |
| Gross Profit | $177,414 | $54,619 | $2,932 | -$763 |
| % Margin | 90.3% | 91.6% | 79.5% | – |
| EBITDA | -$109,625 | -$227,434 | -$294,553 | -$205,593 |
| % Margin | -55.8% | -381.6% | -7,991.1% | – |
| Net Income | -$140,039 | -$262,140 | -$311,458 | -$206,356 |
| % Margin | -71.3% | -439.8% | -8,449.8% | – |
| EPS Diluted | -1.16 | -3.78 | -5.66 | -4.17 |
| % Growth | 69.3% | 33.2% | -35.7% | – |
| Operating Cash Flow | -$112,158 | -$247,057 | -$257,715 | -$174,627 |
| Capital Expenditures | -$143 | -$428 | -$23,283 | -$995 |
| Free Cash Flow | -$112,301 | -$247,485 | -$280,998 | -$175,622 |